NCCRED Clinical Research Scholarship Program - now open!

NCCRED has developed a Clinical Research Scholarship Program to build the scope and capacity of clinical research on emerging drugs across the drug and alcohol sector. This is a national program open to clinicians at all levels, anywhere in Australia. NCCRED is opening TWO new competitive rounds which will give financial and research support allowing recipients to conduct a new research project. The rounds will have a focus on the following areas:

Good Clinical Practice training (ICH-GCP) - expressions of interest

GCP training is essential for anyone involved in clinical trials and in clinical research as it provides the fundamentals for the conduct of ethical research. NCCRED provides training and certification to clinicians and academics in the Drug and Alcohol Sector as a key element to its research education agenda. Participants who complete the training receive Transcelerate-accredited certification which is internationally recognised and valid for up to 3 years. 

NCCRED symposium: Innovations in therapeutic practice for methamphetamine use disorder

Save the Date: Friday 20th November 11am

We wish we could see you all face to face, but this year it will be done virtually to accommodate COVID-19 restrictions. 

The 2020 symposium will focus on innovations in therapeutic practice for methamphetamine disorder. The symposium brings together leading national researchers, including presentations from recipients of NCCRED’s Round 2 Seed Funding Program. Recipients will share the most up-to-date aspects of their work and research around methamphetamine and emerging drug use. 

Guest International Presenter: Dr David Goodman-Meza

David Goodman-Meza, MD, MAS, is an Assistant Professor in the Division of Infectious Diseases at the David Geffen School of Medicine at University of California, Los Angeles, USA. Dr. Goodman-Meza is a Mexican-American physician-scientist.  

He is a recipient of an NIDA K08 Career Development Award where he is training in the use of natural language processing and machine learning to evaluate outcomes of people who inject drugs who are admitted due to Staphylococcus aureus bacteremia. He is also the Los Angeles principal investigator on a NIDA Clinical Trials network study evaluating buprenorphine for treatment of methamphetamine use disorder.

Australian methamphetamine-related clinical guidelines Matrix

NCCRED commissioned the National Centre for Education and Training on Addiction (NCETA) to review Australian methamphetamine-related clinical guidelines.

Twenty-seven methamphetamine-related clinical guidelines were identified, some of which solely addressed methamphetamine (or stimulants) specifically, while others were generic but had component parts of relevance.

From this, NCETA developed a purpose-built framework to map each guideline according to treatment setting and target population. The methamphetamine-related guidelines matrix is an online representation of the framework developed by NCETA.

The National Centre for Clinical Research on Emerging Drugs is made up of a consortium of the following four institutions